Welcome to BioSeeker Group!

Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?

Additional Information

Published Date Mar 1, 2010
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1289
PDF Fact Sheet View Fact Sheet for the report Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place? in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?.

    To find out more about Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

The antibody market represents the fastest-growing segment within the pharmaceutical industry. As such it has become a complex and crowded market place. This is particularly true for the cancer market. When navigating in the competitive landscape of antibody therapeutics in oncology one has to consider available options for your own drug pipeline as well as the position of others.

This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any antibody drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights 4
3 Methodologies 6
4 Table of Contents 8
4.1 List of Figures 20
4.2 List of Tables 20
5 Introduction 30
5.1 Background to the Antibody Therapeutic Market 30
5.2 The Scope of this Report 30
5.3 Definitions 35
5.4 Abbreviations 35
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 36
6.1 Drug Repositioning in Oncology 36
6.2 Introduction to Antibody Therapeutic Targets in Oncology 37
6.2.1 Antigen Binding Targets 41
6.2.2 Auxiliary Transport Protein Activity Targets 42
6.2.3 B Cell Receptor Activity Targets 43
6.2.4 Carboxypeptidase Activity Targets 44
6.2.5 Catalytic Activity Targets 45
6.2.6 Cell Adhesion Molecule Activity Targets 47
6.2.7 Cell Adhesion Molecule Activity Targets 48
6.2.8 Chaperone Activity Targets 63
6.2.9 Chemokine Activity Targets 66
6.2.10 Cofactor Binding Targets 68
6.2.11 Complement Activity Targets 70
6.2.12 Cysteine-Type Peptidase Activity Targets 74
6.2.13 Cytokine Activity Targets 75
6.2.14 Defense/immunity Protein Activity Targets 80
6.2.15 DNA Topoisomerase Activity Targets 81
6.2.16 Extracellular Ligand-Gated Ion Channel Activity Targets 83
6.2.17 Extracellular Matrix Structural Constituent Targets 84
6.2.18 G-protein Coupled Receptor Activity Targets 88
6.2.19 Growth Factor Activity Targets 93
6.2.20 Hormone Activity Targets 105
6.2.21 Hydrolase Activity Targets 106
6.2.22 Intracellular Ligand-Gated Ion Channel Activity Targets 108
6.2.23 Isomerase Activity Targets 109
6.2.24 Kinase Binding Targets 110
6.2.25 Lipid Kinase Activity Targets 111
6.2.26 Metallopeptidase Activity Targets 113
6.2.27 MHC Class I Receptor Activity Targets 115
6.2.28 Molecular Function Unknown Targets 116
6.2.29 Oxidoreductase Activity Targets 133
6.2.30 Peptidase Activity Targets 134
6.2.31 Peptide Hormone Targets 136
6.2.32 Protease Inhibitor Activity Targets 137
6.2.33 Protease Inhibitor Activity Targets 138
6.2.34 Protein Binding Targets 139
6.2.35 Protein Serine/Threonine Kinase Activity Targets 141
6.2.36 Receptor Activity Targets 143
6.2.37 Receptor Binding Targets 195
6.2.38 Receptor Signaling Complex Scaffold Activity Targets 204
6.2.39 RNA-directed DNA Polymerase Activity Targets 207
6.2.40 Serine-type Peptidase Activity Targets 208
6.2.41 Structural Constituent of Cytoskeleton Targets 211
6.2.42 T cell Receptor Activity Targets 212
6.2.43 Transcription Factor Activity Targets 214
6.2.44 Transcription Regulator Activity Targets 217
6.2.45 Transmembrane Receptor Activity Targets 220
6.2.46 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 226
6.2.47 Transporter Activity Targets 252
6.2.48 Unclassified Targets 256
6.3 The Cancer Genome Project and Antibody Therapeutic Targets in Oncology 257
6.3.1 Antibody Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 257
6.4 Structure-based Drug Design in Antibody Therapeutics is Stimulated by Available Structure Data on Biological Targets 261
6.5 Target-Target Interactions among Identified Antibody Therapeutics Targets in Oncology 265
6.6 The Drug-Target Interactome 271
6.7 Protein Expression Levels of Identified Antibody Therapeutic Targets in Oncology 276
6.8 Pathway Analysis of Cancer Antibody Therapeutic Targets 281
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Antibody Therapeutic Pipeline? 320
7.1 Terminated Drug Target Profiles of Cancer Antibody Drugs 325
7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology 330
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology 332
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology 334
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology 339
7.6 Preclinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology 344
7.7 Development Profiles of All Antibody Drugs in Oncology 351
7.8 The Competition Through Close Mechanistic Approximation of Antibody Cancer Therapeutics 375
8 Selecting Cancer Indications for Antibody Therapeutics 384
8.1 Acute Lymphocytic Leukemia 387
8.2 Acute Myelogenous Leukemia 389
8.3 Basal Cell Cancer 391
8.4 B-cell Lymphoma 392
8.5 Biliary Cancer 394
8.6 Bladder Cancer 395
8.7 Bone Cancer 397
8.8 Brain Cancer 398
8.9 Breast Cancer 400
8.10 Cancer (general) 404
8.11 Cancer Diagnosis 406
8.12 Cancer Fatigue 408
8.13 Carcinoid Tumor 408
8.14 Cervical Cancer 409
8.15 Chemotherapy-induced Anemia 410
8.16 Chemotherapy-induced Bone Marrow Injury (general) 410
8.17 Chemotherapy-induced Injury (general) 411
8.18 Chemotherapy-induced Thrombocytopenia 411
8.19 Chronic Lymphocytic Leukemia 412
8.20 Chronic Myelogenous Leukemia 415
8.21 CNS Cancer 416
8.22 Colorectal Cancer 417
8.23 Endometrial Cancer 421
8.24 Ewing’s Sarcoma 422
8.25 Fallopian Tube Cancer 423
8.26 Gastrointestinal Cancer (general) 424
8.27 Gastrointestinal Stomach Cancer 426
8.28 Gastrointestinal Stromal Cancer 428
8.29 Genitourinary Cancer 429
8.30 Hairy Cell Leukemia 430
8.31 Head and Neck Cancer 431
8.32 Hematological Cancer (general) 433
8.33 Hodgkin’s Lymphoma 434
8.34 Leiomyo Sarcoma 436
8.35 Leukemia (general) 437
8.36 Liver Cancer 438
8.37 Lung Cancer (general) 440
8.38 Lymphoma (general) 442
8.39 Melanoma 443
8.40 Merkel Cell Carcinoma 446
8.41 Mesothelioma 447
8.42 Myelodysplastic Syndrome 448
8.43 Myeloma 449
8.44 Nasopharyngeal Cancer 451
8.45 Neuroblastoma 451
8.46 Neuroectodermal Sarcoma 452
8.47 Neuroendocrine Cancer (general) 453
8.48 non-Hodgkin’s Lymphoma 454
8.49 Non-Small Cell Lung Cancer 458
8.50 Oesophageal Cancer 461
8.51 Osteo Sarcoma 463
8.52 Ovarian Cancer 464
8.53 Pancreatic Cancer 468
8.54 Peritoneal Cancer 471
8.55 Prostate Cancer 473
8.56 Renal Cancer 476
8.57 Rhabdomyo Sarcoma 478
8.58 Sarcoma (general) 479
8.59 Skin Cancer (general) 480
8.60 Small Cell Lung Cancer 481
8.61 Soft Tissue Sarcoma 484
8.62 Solid Tumor 485
8.63 Squamous Cell Cancer 486
8.64 Synovial Sarcoma 487
8.65 T-cell Lymphoma 488
8.66 Testicular Cancer 489
8.67 Thyroid Cancer 490
8.68 Unspecified Cancer Indication 492
8.69 Vaccine Adjunct 499
9 Portfolio Planning: Competitive Benchmarking of Antibody Cancer Therapeutic Pipeline by Investigator 500
9.1 A&G Pharmaceutical 502
9.2 Abiogen 505
9.3 Ablynx 510
9.4 AC Immune 513
9.5 Access 516
9.6 Actinium Pharmaceuticals 520
9.7 Active Biotech 524
9.8 Adherex 527
9.9 Affibody 530
9.10 Affimed Therapeutics 534
9.11 Affitech 538
9.12 AGY Therapeutics 542
9.13 Aida Pharmaceuticals 545
9.14 Alder Biopharmaceuticals 549
9.15 Alethia Biotherapeutics 553
9.16 Alexion 556
9.17 Algeta 560
9.18 Amgen 564
9.19 Antisoma 575
9.20 Aphios 579
9.21 Arana Therapeutics 583
9.22 Arca biopharma 586
9.23 Astellas 589
9.24 AstraZeneca 593
9.25 Attenuon 604
9.26 AVEO 607
9.27 Bayer 611
9.28 Berkeley Lab 615
9.29 Biocon 618
9.30 Biogen Idec 621
9.31 BioInvent 631
9.32 Biolex 634
9.33 BioLineRx 638
9.34 Biosceptre 641
9.35 Biotecnol 644
9.36 Boehringer Ingelheim 649
9.37 Bristol-Myers Squibb 652
9.38 BTG 664
9.39 Cancer Innovations 668
9.40 Cancer Research Technology 671
9.41 Celldex Therapeutics 681
9.42 Celtic Pharma 685
9.43 Center of Molecular Immunology 689
9.44 CG Therapeutics 695
9.45 Circadian Technologies 698
9.46 CuraGen 701
9.47 CureTech 704
9.48 Curis 707
9.49 CytImmune Sciences 710
9.50 Daiichi Sankyo 713
9.51 Dendreon 717
9.52 Dompe 720
9.53 Dyax 723
9.54 Eisai 727
9.55 Elan 731
9.56 Eli Lilly 734
9.57 Epitomics 751
9.58 EUSA Pharma 756
9.59 Facet Biotech 759
9.60 Faron Pharmaceuticals 765
9.61 Favrille 768
9.62 FibroGen 772
9.63 Five Prime Therapeutics 775
9.64 Fusion Antibodies 778
9.65 Galaxy Biotech 781
9.66 GammaCan 784
9.67 Ganymed Pharmaceuticals 788
9.68 Gene Techno Science 792
9.69 Genentech 795
9.70 Genmab 803
9.71 GenPat77 816
9.72 Genzyme 819
9.73 GlaxoSmithKline 823
9.74 Gliknik 828
9.75 Glycotope 834
9.76 Green Cross 841
9.77 GTC Biotherapeutics 846
9.78 Hoffmann-La Roche 850
9.79 Human Genome Sciences 878
9.80 IDM Pharma 884
9.81 ImClone Systems 889
9.82 ImmunoCellular Therapeutics 894
9.83 ImmunoGen 898
9.84 Immunomedics 907
9.85 Innate Pharma 924
9.86 InNexus Biotechnology 928
9.87 Intracel 936
9.88 ISA Pharmaceuticals 940
9.89 ISU ABXIS 944
9.90 Johnson & Johnson 949
9.91 Kaketsuken 956
9.92 KaloBios 959
9.93 Kirin Pharma 962
9.94 Kissei 966
9.95 Kyowa Hakko Kirin 970
9.96 LFB Biotechnologies 974
9.97 MacroGenics 977
9.98 MAT Biopharma 982
9.99 Medarex 986
9.100 MediGene 991
9.101 MedImmune 995
9.102 Menarini 999
9.103 Merck & Co 1002
9.104 Merck KGaA 1008
9.105 Merrimack 1015
9.106 Micromet 1018
9.107 MorphoSys 1030
9.108 Neovacs 1033
9.109 Neuren 1037
9.110 NKT Therapeutics 1040
9.111 Non-industrial Sources 1043
9.112 Northwest Biotherapeutics 1048
9.113 Novartis 1051
9.114 OncoMed 1059
9.115 Onyvax 1062
9.116 Oxford BioMedica 1065
9.117 Paladin Labs 1068
9.118 Panacea 1073
9.119 PanGenetics 1077
9.120 Patrys 1081
9.121 Pepscan Therapeutics 1085
9.122 Peregrine Pharmaceuticals 1090
9.123 Pfizer 1095
9.124 Philogen 1105
9.125 Pierre Fabre 1108
9.126 Prima Biomed 1114
9.127 ProCell Therapeutics 1117
9.128 Prochon Biotech 1120
9.129 Progenics Pharmaceuticals 1123
9.130 Protherics 1126
9.131 Ramot 1129
9.132 Recepta biopharma 1132
9.133 Receptor BioLogix 1135
9.134 Regeneron 1139
9.135 Sanofi-Aventis 1144
9.136 Scancell 1147
9.137 Seattle Genetics 1150
9.138 Sirtex Medical 1158
9.139 Sunol Molecular 1162
9.140 SuppreMol 1165
9.141 Switch Pharma 1168
9.142 Symphogen 1171
9.143 SynerGene Therapeutics 1176
9.144 Takeda 1179
9.145 Targa Therapeutics 1182
9.146 TeGenero 1187
9.147 Teva 1190
9.148 Therapure Biopharma 1193
9.149 ThromboGenics 1196
9.150 Titan Pharmaceuticals 1199
9.151 Tolerx 1204
9.152 Tracon Pharmaceuticals 1207
9.153 Trillium Therapeutics 1210
9.154 Trion Pharma 1213
9.155 Trubion 1218
9.156 UCB 1221
9.157 United Therapeutics 1225
9.158 Vaccinex 1228
9.159 VasGene Therapeutics 1233
9.160 Viragen 1236
9.161 Viventia Biotech 1239
9.162 Wilex 1242
9.163 Xencor 1245
9.164 Xerion 1257
9.165 Xoma 1262
9.166 Y’s Therapeutics 1266
10 Disclaimer 1269
11 Drug Index 1270
12 Company Index 1282

List of Figures
Figure 1: Visualization of Target-Target Interactions among Antibody Drug Targets in Oncology 270
Figure 2: The Drug-Protein Interactome of Antibody Drugs –Large Clusters 272
Figure 3: The Drug-Protein Interactome of Antibody Drugs – Small Clusters 273
Figure 4: Head-to-Head Targeting Interactome of Antibody Drugs – Large Clusters 274
Figure 5: Head-to-Head Targeting Interactome of Antibody Drugs – Small Clusters 275

List of Tables
Table 1: Head to Head Competition among Apoptopic Drugs in Oncology 31
Table 2: Overall Breakdown of the Included Antibody Pipeline by Cancer Indication and Stage of Development 31
Table 3: Overview of Drug Target Profile Themes 37
Table 4: Terminally Ceased Therapeutic Antibody Targets in Oncology 38
Table 5: Drug Targets of Antibody Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 258
Table 6: Identity of Antibody Drug Targets with Available Biological Structures 261
Table 7: Number of Target-Target Interactions among Antibody Drug Targets in Oncology 265
Table 8: Antibody Drug Targets with Available Protein Expression Profiles 276
Table 9: Pathway Summary 281
Table 10: Drug Targets without any Identified Assigned Pathways 281
Table 11: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology 284
Table 12: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology 299
Table 13: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology 318
Table 14: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 320
Table 15: Top Competitive Antibody Target Profiles in Oncology 321
Table 16: Terminated Drug Target Strategies of Antibody Drugs in Oncology 325
Table 17 New and Unique Antibody Target Strategies in Cancer Currently in Pre-Registration to Marketed 330
Table 18: The Competition Through Close Mechanistic Approximation Between Pre-registration to Marketed Antibody Drugs in Oncology 331
Table 19: New and Unique Antibody Target Strategies in Cancer Currently in Phase III Clinical Development 332
Table 20: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Oncology 333
Table 21: New and Unique Antibody Target Strategies in Cancer Currently in Phase II Clinical Development 334
Table 22: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Oncology 336
Table 23 New and Unique Antibody Target Strategies in Cancer Currently in Phase I Clinical Development 339
Table 24: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Oncology 342
Table 25: New and Unique Antibody Target Strategies in Oncology Currently in Preclinical Development 344
Table 26: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Oncology 348
Table 27: The Progression, Maturity and Competitive Comparison of Antibody Drug Target Profiles in Cancer Drug Development 351
Table 28: The Competition Through Close Mechanistic Approximation Among All Antibody Drugs in Oncology 375
Table 29: Competitive Summary of Antibody Drugs by Cancer Indication 384
Table 30: Drug Target Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia 387
Table 31: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 388
Table 32: Drug Target Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia 389
Table 33: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 390
Table 34: Drug Target Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer 391
Table 35: Drug Target Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma 392
Table 36: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 393
Table 37: Drug Target Profiles of Antibody Drugs for the Treatment of Biliary Cancer 394
Table 38: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs 394
Table 39: Drug Target Profiles of Antibody Drugs for the Treatment of Bladder Cancer 395
Table 40: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 396
Table 41: Drug Target Profiles of Antibody Drugs for the Treatment of Bone Cancer 397
Table 42: Drug Target Profiles of Antibody Drugs for the Treatment of Brain Cancer 398
Table 43: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 399
Table 44: Drug Target Profiles of Antibody Drugs for the Treatment of Breast Cancer 400
Table 45: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 402
Table 46: Drug Target Profiles of Antibody Drugs for the Treatment of Cancer (general) 404
Table 47: The Competition through Close Mechanistic Approximation between Cancer (general) 404
Table 48: Drug Target Profiles of Antibody Drugs for Cancer Diagnosis 406
Table 49: The Competition through Close Mechanistic Approximation between Cancer Diagnosis Drugs 407
Table 50: Drug Target Profiles of Antibody Drugs for the Treatment of Cancer Fatigue 408
Table 51: Drug Target Profiles of Antibody Drugs for the Treatment of Carcinoid Tumor 408
Table 52: Drug Target Profiles of Antibody Drugs for the Treatment of Cervical Cancer 409
Table 53: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 409
Table 54: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Anemia 410
Table 55: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Bone Marrow Injury (general) 410
Table 56: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Injury (general) 411
Table 57: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Thrombocytopenia 411
Table 58: Drug Target Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia 412
Table 59: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 413
Table 60: Drug Target Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia 415
Table 61: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia 415
Table 62: Drug Target Profiles of Antibody Drugs for the Treatment of CNS Cancer 416
Table 63: Drug Target Profiles of Antibody Drugs for the Treatment of Colorectal Cancer 417
Table 64: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 419
Table 65: Drug Target Profiles of Antibody Drugs for the Treatment of Endometrial Cancer 421
Table 66: Drug Target Profiles of Antibody Drugs for the Treatment of Ewing’s Sarcoma 422
Table 67: The Competition through Close Mechanistic Approximation between Ewing’s Sarcoma Drugs 422
Table 68: Drug Target Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer 423
Table 69: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general) 424
Table 70: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 425
Table 71: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer 426
Table 72: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 427
Table 73: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer 428
Table 74: Drug Target Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer 429
Table 75: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs 429
Table 76: Drug Target Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia 430
Table 77: Drug Target Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer 431
Table 78: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 432
Table 79: Drug Target Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general) 433
Table 80: Drug Target Profiles of Antibody Drugs for the Treatment of Hodgkin’s Lymphoma 434
Table 81: The Competition through Close Mechanistic Approximation between Hodgkin’s Lymphoma Drugs 435
Table 82: Drug Target Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma 436
Table 83: Drug Target Profiles of Antibody Drugs for the Treatment of Leukemia (general) 437
Table 84: Drug Target Profiles of Antibody Drugs for the Treatment of Liver Cancer 438
Table 85: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 439
Table 86: Drug Target Profiles of Antibody Drugs for the Treatment of Lung Cancer (general) 440
Table 87: The Competition through Close Mechanistic Approximation between Lung Cancer (general)Drugs 441
Table 88: Drug Target Profiles of Antibody Drugs for the Treatment of Lymphoma (general) 442
Table 89: Drug Target Profiles of Antibody Drugs for the Treatment of Melanoma 443
Table 90: The Competition through Close Mechanistic Approximation between Melanoma Drugs 444
Table 91: Drug Target Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma 446
Table 92: Drug Target Profiles of Antibody Drugs for the Treatment of Mesothelioma 447
Table 93: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 447
Table 94: Drug Target Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome 448
Table 95: Drug Target Profiles of Antibody Drugs for the Treatment of Myeloma 449
Table 96: The Competition through Close Mechanistic Approximation between Myeloma Drugs 450
Table 97: Drug Target Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer 451
Table 98: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroblastoma 451
Table 99: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma 452
Table 100: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general) 453
Table 101: Drug Target Profiles of Antibody Drugs for the Treatment of non-Hodgkin’s Lymphoma 454
Table 102: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs 456
Table 103: Drug Target Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer 458
Table 104: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 460
Table 105: Drug Target Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer 461
Table 106: The Competition through Close Mechanistic Approximation between Oesophageal Cancer 462
Table 107: Drug Target Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma 463
Table 108: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs 463
Table 109: Drug Target Profiles of Antibody Drugs for the Treatment of Ovarian Cancer 464
Table 110: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 467
Table 111: Drug Target Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer 468
Table 112: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 470
Table 113: Drug Target Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer 471
Table 114: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 472
Table 115: Drug Target Profiles of Antibody Drugs for the Treatment of Prostate Cancer 473
Table 116: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 475
Table 117: Drug Target Profiles of Antibody Drugs for the Treatment of Renal Cancer 476
Table 118: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 477
Table 119: Drug Target Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma 478
Table 120: The Competition through Close Mechanistic Approximation between rhabdomyo sarcoma Drugs 478
Table 121: Drug Target Profiles of Antibody Drugs for the Treatment of Sarcoma (general) 479
Table 122: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 479
Table 123: Drug Target Profiles of Antibody Drugs for the Treatment of Skin Cancer (general) 480
Table 124: Drug Target Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer 481
Table 125: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 483
Table 126: Drug Target Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma 484
Table 127: Drug Target Profiles of Antibody Drugs for the Treatment of Solid Tumor 485
Table 128: Drug Target Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer 486
Table 129: Drug Target Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma 487
Table 130: Drug Target Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma 488
Table 131: Drug Target Profiles of Antibody Drugs for the Treatment of Testicular Cancer 489
Table 132: Drug Target Profiles of Antibody Drugs for the Treatment of Thyroid Cancer 490
Table 133: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 490
Table 134: Drug Target Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Indication 492
Table 135: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 496
Table 136: Drug Target Profiles of Antibody Drugs as Vaccine Adjunct 499
Table 137: A&G Pharmaceutical’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 502
Table 138: Abiogen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 505
Table 139: Ablynx’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 510
Table 140: AC Immune’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 513
Table 141: Access’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 516
Table 142: Actinium Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 520
Table 143: Active Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 524
Table 144: Adherex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 527
Table 145: Affibody’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 530
Table 146: Affimed Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 534
Table 147: Affitech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 538
Table 148: AGY Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 542
Table 149: Aida Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 545
Table 150: Alder Biopharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 549
Table 151: Alethia Biotherapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 553
Table 152: Alexion’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 556
Table 153: Algeta’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 560
Table 154: Amgen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 564
Table 155: Antisoma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 575
Table 156: Aphios’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 579
Table 157: Arana Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 583
Table 158: Arca biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 586
Table 159: Astellas’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 589
Table 160: AstraZeneca’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 593
Table 161: Attenuon’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 604
Table 162: AVEO’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 607
Table 163: Bayer’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 611
Table 164: Berkeley Lab’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 615
Table 165: Biocon’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 618
Table 166: Biogen Idec’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 621
Table 167: BioInvent’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 631
Table 168: Biolex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 634
Table 169: BioLineRx’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 638
Table 170: Biosceptre’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 641
Table 171: Biotecnol’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 644
Table 172: Boehringer Ingelheim’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 649
Table 173: Bristol-Myers Squibb’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 652
Table 174: BTG’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 664
Table 175: Cancer Innovations’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 668
Table 176: Cancer Research Technology’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 671
Table 177: Celldex Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 681
Table 178: Celtic Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 685
Table 179: Center of Molecular Immunology’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 689
Table 180: CG Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 695
Table 181: Circadian Technologies’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 698
Table 182: CuraGen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 701
Table 183: CureTech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 704
Table 184: Curis’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 707
Table 185: CytImmune Sciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 710
Table 186: Daiichi Sankyo’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 713
Table 187: Dendreon’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 717
Table 188: Dompe’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 720
Table 189: Dyax’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 723
Table 190: Eisai’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 727
Table 191: Elan’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 731
Table 192: Eli Lilly’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 734
Table 193: Epitomics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 751
Table 194: EUSA Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 756
Table 195: Facet Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 759
Table 196: Faron Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 765
Table 197: Favrille’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 768
Table 198: FibroGen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 772
Table 199: Five Prime Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 775
Table 200: Fusion Antibodies’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 778
Table 201: Galaxy Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 781
Table 202: GammaCan’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 784
Table 203: Ganymed Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 788
Table 204: Gene Techno Science’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 792
Table 205: Genentech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 795
Table 206: Genmab’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 803
Table 207: GenPat77’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 816
Table 208: Genzyme’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 819
Table 209: GlaxoSmithKline’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 823
Table 210: Gliknik’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 828
Table 211: Glycotope’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 834
Table 212: Green Cross’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 841
Table 213: GTC Biotherapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 846
Table 214: Hoffmann-La Roche’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 850
Table 215: Human Genome Sciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 878
Table 216: IDM Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 884
Table 217: ImClone Systems’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 889
Table 218: ImmunoCellular Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 894
Table 219: ImmunoGen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 898
Table 220: Immunomedics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 907
Table 221: Innate Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 924
Table 222: InNexus Biotechnology’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 928
Table 223: Intracel’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 936
Table 224: ISA Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 940
Table 225: ISU ABXIS’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 944
Table 226: Johnson & Johnson’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 949
Table 227: Kaketsuken’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 956
Table 228: KaloBios’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 959
Table 229: Kirin Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 962
Table 230: Kissei’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 966
Table 231: Kyowa Hakko Kirin’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 970
Table 232: LFB Biotechnologies’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 974
Table 233: MacroGenics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 977
Table 234: MAT Biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 982
Table 235: Medarex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 986
Table 236: MediGene’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 991
Table 237: MedImmune’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 995
Table 238: Menarini’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 999
Table 239: Merck & Co’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1002
Table 240: Merck KGaA’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1008
Table 241: Merrimack’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1015
Table 242: Micromet’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1018
Table 243: MorphoSys’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1030
Table 244: Neovacs’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1033
Table 245: Neuren’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1037
Table 246: NKT Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1040
Table 247: Non-industrial source’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1043
Table 248: Northwest Biotherapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1048
Table 249: Novartis’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1051
Table 250: OncoMed’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1059
Table 251: Onyvax’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1062
Table 252: Oxford BioMedica’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1065
Table 253: Paladin Labs’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1068
Table 254: Panacea’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1073
Table 255: PanGenetics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1077
Table 256: Patrys’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1081
Table 257: Pepscan Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1085
Table 258: Peregrine Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1090
Table 259: Pfizer’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1095
Table 260: Philogen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1105
Table 261: Pierre Fabre’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1108
Table 262: Prima Biomed’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1114
Table 263: ProCell Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1117
Table 264: Prochon Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1120
Table 265: Progenics Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1123
Table 266: Protherics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1126
Table 267: Ramot’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1129
Table 268: Recepta biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1132
Table 269: Receptor BioLogix’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1135
Table 270: Regeneron’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1139
Table 271: Sanofi-Aventis’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1144
Table 272: Scancell’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1147
Table 273: Seattle Genetics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1150
Table 274: Sirtex Medical’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1158
Table 275: Sunol Molecular’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1162
Table 276: SuppreMol’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1165
Table 277: Switch Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1168
Table 278: Symphogen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1171
Table 279: SynerGene Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1176
Table 280: Takeda’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1179
Table 281: Targa Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1182
Table 282: TeGenero’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1187
Table 283: Teva’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1190
Table 284: Therapure Biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1193
Table 285: ThromboGenics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1196
Table 286: Titan Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1199
Table 287: Tolerx’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1204
Table 288: Tracon Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1207
Table 289: Trillium Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1210
Table 290: Trion Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1213
Table 291: Trubion’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1218
Table 292: UCB’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1221
Table 293: United Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1225
Table 294: Vaccinex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1228
Table 295: VasGene Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1233
Table 296: Viragen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1236
Table 297: Viventia Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1239
Table 298: Wilex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1242
Table 299: Xencor’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1245
Table 300: Xerion’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1257
Table 301: Xoma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1262
Table 302: Y’s Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1266

This report includes 168 investigators plus their collaborators:
A&G Pharmaceutical
Abiogen
Ablynx
AC Immune
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Affibody
Affimed Therapeutics
Affitech
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Amgen
Antisoma
Aphios
Arana Therapeutics
Arca biopharma
Astellas
AstraZeneca
Attenuon
AVEO
Bayer
Berkeley Lab
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
Biosceptre
Biotecnol
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Cancer Innovations
Cancer Research Technology
Celldex Therapeutics
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
Circadian Technologies
CuraGen
CureTech
Curis
CytImmune Sciences
Daiichi Sankyo
Dendreon
Dompe
Dyax
Eisai
Elan
Eli Lilly
Epitomics
EUSA Pharma
Facet Biotech
Faron Pharmaceuticals
Favrille
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genentech
Genmab
GenPat77
Genzyme
GlaxoSmithKline
Gliknik
Glycotope
Green Cross
GTC Biotherapeutics
Hoffmann-La Roche
Human Genome Sciences
IDM Pharma
ImClone Systems
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
Innate Pharma
InNexus Biotechnology
Intracel
ISA Pharmaceuticals
ISU ABXIS
Johnson & Johnson
Kaketsuken
KaloBios
Kirin Pharma
Kissei
Kyowa Hakko Kirin
LFB Biotechnologies
MacroGenics
MAT Biopharma
Medarex
MediGene
MedImmune
Menarini
Merck & Co
Merck KGaA
Merrimack
Micromet
MorphoSys
Neovacs
Neuren
NKT Therapeutics
Northwest Biotherapeutics
Novartis
OncoMed
Onyvax
Oxford BioMedica
Paladin Labs
Panacea
PanGenetics
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Pfizer
Philogen
Pierre Fabre
Prima Biomed
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
Protherics
Ramot
Recepta biopharma
Receptor BioLogix
Regeneron
Sanofi-Aventis
Scancell
Seattle Genetics
Sirtex Medical
Sunol Molecular
SuppreMol
Switch Pharma
Symphogen
SynerGene Therapeutics
Takeda
Targa Therapeutics
TeGenero
Teva
Therapure Biopharma
ThromboGenics
Titan Pharmaceuticals
Tolerx
Tracon Pharmaceuticals
Trillium Therapeutics
Trion Pharma
Trubion
UCB
United Therapeutics
Vaccinex
VasGene Therapeutics
Wilex
Viragen
Viventia Biotech
Xencor
Xerion
Xoma
Y’s Therapeutics
This report includes 441 antibody drugs in oncology. From Ceased to Marketed.
A shortlist of drugs included are:
131I-tositumomab
abagovomab
adecatumumab
aflibercept
afutuzumab
AGS-1C4D4
AGS-PSCA
ALD-518
alemtuzumab
ALXN-6000
AME-133
AMG-479
Apomab
bevacizumab
BIIB-022
blinatumomab
BMS-663513
brentuximab vedotin
catumaxomab
cetuximab
cixutumumab
CNTO-328
CNTO-888
conatumumab
CT-011
daratumumab
denosumab
DI-17E6
elotuzumab
EMD-273063
epratuzumab
epratuzumab-Y90
ertumaxomab
F-50035
farletuzumab
figitumumab
fresolimumab
G-250
galiximab
GDC-0449
I-131-labetuzumab
ibritumomab tiuxetan
IMC-3G3
IMGN-901
inotuzumab ozogamicin
intetumumab
IPH-2101
ipilimumab
iratumumab
KW-0761
L19-SIP
lintuzumab
LIP-131I
lucatumumab
lumiliximab
lymphomun
mapatumumab
matuzumab
MCS-110
MDX-1106
milatuzumab
MM-111
MORAb-009
naptumomab estafenatox
natalizumab
necitumumab
nimotuzumab
ocrelizumab
ofatumumab
Onyvax-105
oregovomab
panitumumab
PAT-SC1
pertuzumab
PF-4856884
ramucirumab
RG 3638
RG-1507
rilotumumab
rituximab
robatumumab
Tenarad
tigatuzumab
tocilizumab
trastuzumab
tremelimumab
TRU-016
tucotuzumab celmoleukin
veltuzumab
volociximab
YS-110
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
Zemab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?.
    To find out more about Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


Protein Kinase Therapeutics in Oncology - Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Pancreatic Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Wnt Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 228 companies plus partners who are today developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer across 204 different targets. In addition, there are 2 suspended drugs and another 118 drugs where development has been ceased. Learn More

Other selected research from the 'Biologicals' category:


The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More


Peptides in Oncology: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of peptides. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More